Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting.

ABSTRACT:

Objective

To compare the health impact and economic benefits among individuals who did not receive the human papillomavirus (HPV) vaccine to those who received a single dose, or 2 doses. The comparison was stratified by 4 types of vaccine in conjunction with primary HPV screening in a low/middle-income country setting.

Methods

A Markov model was employed to simulate HPV infection and cervical cancer in a cohort of 100,000 12-year-old girls free of HPV. The study scrutinized 9 strategies: 1 dose and 2 doses of 2vHPV (Cervarix^®), 2vHPV (Cecolin^®), 4vHPV (Gardasil^®), 9vHPV vaccine (Gardasil9^®), and no vaccination. The primary outcome measure was the quality-adjusted life year (QALY) of each strategy. Incremental cost-effectiveness rat

SUBMITTER: Termrungruanglert W 

PROVIDER: S-EPMC11543265 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature